Finasteride
- CAS No.
- 98319-26-7
- Chemical Name:
- Finasteride
- Synonyms
- PROSCAR;Finasteride for peak identification;n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide;MK-906;Andozac;mk-0906;Fistide;PROSTIDE;FINASTID;Propecia
- CBNumber:
- CB9433852
- Molecular Formula:
- C23H36N2O2
- Molecular Weight:
- 372.54
- MDL Number:
- MFCD00869737
- MOL File:
- 98319-26-7.mol
| Melting point | 253 °C |
|---|---|
| alpha | 405 -59° (c = 1 in methanol) |
| Boiling point | 576.6±50.0 °C(Predicted) |
| Density | 1.065±0.06 g/cm3(Predicted) |
| storage temp. | room temp |
| solubility | DMSO: 32 mg/mL, soluble |
| form | solid |
| pka | 14.17±0.70(Predicted) |
| color | white to beige |
| Water Solubility | insoluble |
| Merck | 14,4082 |
| BCS Class | 1 |
| InChIKey | DBEPLOCGEIEOCV-WSBQPABSSA-N |
| LogP | 3.030 |
| CAS DataBase Reference | 98319-26-7(CAS DataBase Reference) |
| NCI Dictionary of Cancer Terms | finasteride |
| FDA UNII | 57GNO57U7G |
| NCI Drug Dictionary | finasteride |
| ATC code | D11AX10,G04CB01 |
| EPA Substance Registry System | 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-(1,1-dimethylethyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)- (98319-26-7) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H302-H360FD | |||||||||
| Precautionary statements | P202-P264-P270-P280-P301+P312-P308+P313 | |||||||||
| Hazard Codes | Xn,T,Xi | |||||||||
| Risk Statements | 22-61-60-36/37/38 | |||||||||
| Safety Statements | 36/37/39-45-53-36-26-24/25 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | CL5245000 | |||||||||
| HS Code | 29379000 | |||||||||
| NFPA 704 |
|
Finasteride price More Price(41)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | BP740 | Finasteride British Pharmacopoeia (BP) Reference Standard | 98319-26-7 | 100MG | $244 | 2024-03-01 | Buy |
| Sigma-Aldrich | 1270402 | Finasteride United States Pharmacopeia (USP) Reference Standard | 98319-26-7 | 200mg | $436 | 2024-03-01 | Buy |
| Sigma-Aldrich | 34202 | Finasteride VETRANAL | 98319-26-7 | 100mg | $174 | 2022-05-15 | Buy |
| TCI Chemical | F0675 | Finasteride >98.0%(GC) | 98319-26-7 | 200mg | $59 | 2024-03-01 | Buy |
| TCI Chemical | F0675 | Finasteride >98.0%(GC) | 98319-26-7 | 1g | $173 | 2024-03-01 | Buy |
Finasteride Chemical Properties,Uses,Production
Indications and Usage
Finasteride is a basic drug to treat benign prostatic hyperplasia and prostatitis, a synthetic 4-nitrogen steroid hormone compound and a sex hormone drug.
It is used for benign prostatic hyperplasia, men's prostatic fat and other diseases. Finasteride is the only oral drug approved by the US Food and Drug Administration (FDA) to treat male pattern baldness.
Mechanisms of Action
Finasteride can selectively inhibit 5α-reductase, changing the conversion process of testosterone into 5α dihydrotestosterone (DHT), decreasing androgen levels in prostate cells, and prostate-specific antigens in serum, decreasing prostate swelling, and increasing urine flow rate, thereby alleviating the symptoms of prostatic hyperplasia. It acts by selectively blocking androgen stimulation of the prostate, but affects sexual function very rarely. Meanwhile, due to blocking of testosterone conversion and reduced synthesis of dihydrotestosterone, it can reduce dihydrotestosterone levels in the serum and scalp hair follicles, recovering the function of previously inhibited hair follicles, promoting hair growth and preventing loss.
clinical trials
Three controlled clinical trials were performed in men (18 to 41 years), with mild-to-moderate degrees of androgenetic alopecia. In these studies, 1879 men ingested either a 1- mg finasteride tablet or placebo tablet once daily for 12 months; after 12 months, finasteride-treated patients were switched to placebo and placebo-treated patients were switched to finasteride and they were followed for an additional 12 months. Clinical improvement was seen as early as 3 months in finasteride-treated patients and hair regrowth continued throughout the trial. Finasteride also had a stabilizing effect on hair loss, which was maintained through the second year of treatment. Hair counts in placebo-treated patients decreased during the study. Finasteride was generally well tolerated in these studies. Some men, however, experienced decreased libido, difficulty in achieving an erection, and decreased semen volume (<2% of patients in each case). These side effects resolved in 58% of the men who continued treatment and completely abated upon discontinuation of the drug.
Description
Finasteride, a novel 4-azasteroid, is a breakthrough in the treatment and control of benign prostatic hyperplasia. Mechanistically, it inhibits the prostatic-specific enzyme 5-alpha reductase, thereby decreasing the conversion of testosterone to dihydrotestosterone. It is reportedly effective in reducing urinary symptoms and prostatic volume and increasing maximal urinary flow rate. Finasteride is also being investigated as a treatment for prostatic cancer.
Chemical Properties
White or off-white crystalline powder. Soluble in chloroform, dimethyl sulfoxide, ethanol, methanol, or n-propanol. Insoluble in propylene glycol or polyethylene glycol 400. Very slightly soluble in 0.1mol/L hydrochloric acid, 0.1mol/L sodium hydroxide solution, or water.
Originator
Merck (U.S.A.)
Uses
Finasteride is an antialopecia agent that Inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone. It is used to treatment of benign prostatic hyperplasia and androgenetic alopecia.
Definition
ChEBI: Finasteride is an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. It has a role as an androgen antagonist, an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a 3-oxo steroid and a delta-lactam. It derives from a hydride of a 5alpha-androstane.
Application
Finasteride is a specific inhibitor of steroid type II 5α-reductase, an intracellular enzyme that converts testosterone to DHT. By inhibiting type II 5α-reductase, this conversion is blocked, resulting in significant decreases in serum and tissue DHT concentrations. Merck & Co. developed finasteride as an oral treatment for androgenetic alopecia after men taking finasteride (5 mg/ day) for prostate enlargement noticed regrowth of their hair. Finasteride is indicated for use in men only. Women of childbearing age cannot take finasteride because it may cause hypospadia (a developmental abnormality of the penis) in the male offspring if taken during pregnancy.
Indications
Finasteride (Proscar) is a 5-reductase inhibitor that blocks the conversion of testosterone to DHT in target tissues. Since DHT is the major intracellular androgen in the prostate, finasteride is effective in suppressing DHT stimulation of prostatic growth and secretory function without markedly affecting libido. It is approved for the treatment of benign prostatic hyperplasia. Although there is usually some regression in the size of the prostate gland following administration of finasteride, clinical response may take 6 to 12 months. If the obstructive symptoms are severe, there is often not enough time to allow this compound to work.The principal adverse effects of finasteride are impotence, decreased libido, and decreased volume of ejaculate. The compound is generally well tolerated in men.
Manufacturing Process
In a flask equipped with an overhead stirrer, a nitrogen inlet, and reflux condenser was placed 840 ml of dry THF and 20.0 g of 17β-carboxylate 17β- carbomethoxy ester of 4-aza-5α-androst-1-en-3-one (synthesized according to Patent US 4,377,584, issued Mar. 22,1883, and J. Med. Chem., 29, 2298 (1986)). The resulting slurry was cooled to -5-10°C, and 27.6 mL of tbutylamine was added. A solution of ethylmagnesium bromide in THF (122 mL, 2 M) was added maintaining the temperature of the reaction mixture below 10°C. The reaction mixture was heated at reflux for 12 hours and was added to a cold (10°C) solution of 25% ammonium chloride in water. The mixture was warmed to 25°C and allowed to settle. The THF solution was separated and concentrated by atmospheric distillation to 200 mL and the product was crystallized by adding approximately 600 mL of dilute aqueous HCl. The resulting white solid was isolated by filtration and was dried at 70°C under vacuum to give 21.7 g (97% yield) 2-butyl-1-(4-carboxybenzyl)-4- chloroimidazole-5-acetic acid of finasteride. The finasteride can be purified by conventional procedures, e.g. recrystallization from methylene chloride/ethyl acetate or acetic acid/water, melting point 261°C.
brand name
Proscar
Therapeutic Function
Antineoplastic
Biological Activity
Antiandrogen that inhibits type II 5 α reductase (IC 50 = 65 nM). Suppresses the conversion of testosterone to dihydrotestosterone. Reduces prostatic dihydrotestosterone levels and prostate size in vivo . Orally active.
Biochem/physiol Actions
Selective 5α-reductase inhibitor; antiandrogen.
Pharmacokinetics
The mean oral bioavailability of finasteride is 65%, as shown in Table 45.4, and is not affected by food. Approximately 90% of circulating finasteride is bound to plasma proteins. Finasteride has been found to cross the blood-brain barrier, but levels in semen were undetectable (<0.2 ng/mL). Finasteride is extensively metabolized in the liver, primarily via CYP3A4 to two major metabolites: monohydroxylation of the t-butyl side chain, which is further metabolized via an aldehyde intermediate to the second metabolite, a monocarboxylic acid. The metabolites show approximately 20% the inhibition of finasteride for 5α-reductase. The mean terminal half-life is approximately 5 to 6 hours in men between 18 and 60 years of age and 8 hours in men older than 70 years of age. Following an oral dose of finasteride, approximately 40% of the dose was excreted in the urine as metabolites and approximately 57% in the feces. Even though the elimination rate of finasteride is decreased in the elderly, no dosage adjustment is necessary. No dosage adjustment is necessary in patients with renal insufficiency. A decrease in the urinary excretion of metabolites was observed in patients with renal impairment, but this was compensated for by an increase in fecal excretion of metabolites. Caution should be used during administration to patients with liver function abnormalities, because finasteride is metabolized extensively in the liver.
Clinical Use
The selective inhibition of the type 2 5α-reductase isozyme produces a rapid reduction in plasma DHT concentration, reaching 65% suppression within 24 hours of administering a 1-mg oral tablet (106). At steady state, finasteride suppresses DHT levels by approximately 70% in plasma and by as much as 85 to 90% in the prostate. The remaining DHT in the prostate likely is the result of type 1 5α-reductase. The mean circulating levels of testosterone and estradiol remained within their physiological concentration range. Long-term therapy with finasteride can reduce clinical significant end points of BPH, such as acute urinary retention or surgery. Finasteride is most effective in men with large prostates. Finasteride has no affinity for the AR and no androgenic, antiandrogenic, estrogenic, antiestrogenic, or progestational effects.
Veterinary Drugs and Treatments
Finasteride may be useful in treating the benign prostatic hypertrophy
in canine patients. Because of the drug’s relative expense and
the long duration of therapy required to see a response, its usefulness
may be limited in veterinary medicine.
It may also be useful in the adjunctive treatment of adrenal disease
in ferrets.
Metabolism
Finasteride is metabolised primarily via the cytochrome P450 3A4 enzyme subfamily. Following an oral dose of 14C-finasteride in man, two metabolites of the drug were identified that possess only a small fraction of the 5α-reductase inhibitory activity of finasteride. 39% of the dose was excreted in the urine in the form of metabolites (virtually no unchanged drug was excreted in the urine) and 57% of total dose was excreted in the faeces.
storage
Store at RT
References
Perifollicular fibrosis: Pathogenetic role in androgenetic alopecia; H.G. Yoo, et al.; Biol. Pharm. Bull. 29, 1246 (2006). DOI:10.1248/BPB.29.1246
Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line: J.M. Golbano, et al.; Int. J. Oncol. 32, 919 (2008) DOI:10.3892/IJO.32.4.919
Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders: S. Paba, et al.; Curr. Pharm. Des. 17, 151 (2011) DOI:10.2174/138161211795049589
Finasteride: An update of its use in the management of symptomatic benign prostatic hyperplasia (a review). M. I. Wilde, K. L. Goa, Drugs 1999, 57, 557. DOI:10.2165/00003495-199957040-00008
Finasteride: a review of its use in male pattern hair loss. K. J. McClellan, A. Markham, Drugs 1999, 57, 111. DOI:10.2165/00003495-199957010-00014
Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer (a review). L. N. Thomas, R. C. Douglas, C. B. Lazier, C. K. L. Too, R. S. Rittmaster, D. J. Tindall, Eur. Urol. 2008, 53, 244. DOI:10.1016/J.EURURO.2007.10.052
Finasteride Preparation Products And Raw materials
Raw materials
1of3
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Baoji Guokang Bio-Technology Co., Ltd. | 0917-3909592 13892490616 | gksales1@gk-bio.com | China | 9339 | 58 |
| Hong Kong Excellence Biotechnology Co., Ltd. | +86-86-18838029171 +8618126314766 | ada@sh-teruiop.com | China | 893 | 58 |
| Shaanxi Pioneer Biotech Co., Ltd . | +8613259417953 | sales@pioneerbiotech.com | China | 3000 | 58 |
| Wuhan senwayer century chemical Co.,Ltd | +undefined-27-86652399 +undefined13627115097 | market02@senwayer.com | China | 874 | 58 |
| Hebei Lingding Biotechnology Co., Ltd. | +86-18031140164 +86-19933155420 | erin@hbldbiotech.com | China | 878 | 58 |
| hebei hongtan Biotechnology Co., Ltd | +86-86-1913198-3935 +8617331935328 | sales03@chemcn.cn | China | 951 | 58 |
| Guangdong Tuoyuan Biotechnology Co., LTD | +85267545345 | sterodschina@gmail.com | China | 115 | 58 |
| Shanghai Aosiris new Material Technology Co., LTD | 86-15139564871 +8615139564871 | wrjmoon2000@163.com | China | 354 | 58 |
| Shaanxi TNJONE Pharmaceutical Co., Ltd | +86-13474506593 +86-13474506593 | sarah@tnjone.com | China | 874 | 58 |
| Firsky International Trade (Wuhan) Co., Ltd | +8615387054039 | admin@firsky-cn.com | China | 436 | 58 |
Related articles
- The mechanism of action and side effects of Finasteride
- Finasteride is a 5-alpha reductase inhibitor mainly used to treat benign prostatic hyperplasia and alopecia.
- Dec 7，2023
- Pharmacological action and Preparation of Finasteride
- Finasteride is a 4-azasteroid that can selectively and competitively inhibits 5α-reductase activity, has a good inhibitory ef....
- Aug 1，2022
View Lastest Price from Finasteride manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-04-25 | Finasteride
98319-26-7
|
US $100.00 / kg | 1kg | >99% | 20tons | Hong Kong Excellence Biotechnology Co., Ltd. | |
 |
2024-04-24 | Finasteride / Proscar
98319-26-7
|
US $30.00 / Box | 1Box | 99.99% | 10000000000 | zhuzhou dingcheng meihei comestic co.,ltd | |
 |
2024-04-23 | Finasteride
98319-26-7
|
US $0.00 / kg | 1kg | 99% | 20tons | Shaanxi TNJONE Pharmaceutical Co., Ltd |
-
- Finasteride
98319-26-7
- US $100.00 / kg
- >99%
- Hong Kong Excellence Biotechnology Co., Ltd.
-
- Finasteride / Proscar
98319-26-7
- US $30.00 / Box
- 99.99%
- zhuzhou dingcheng meihei comestic co.,ltd
-
- Finasteride
98319-26-7
- US $0.00 / kg
- 99%
- Shaanxi TNJONE Pharmaceutical Co., Ltd
98319-26-7(Finasteride)Related Search:
1of4